论文部分内容阅读
目的:探讨晚期结肠癌癌组织中核苷酸切除修复交叉互补基因1(excision repair cross-complementing gene l,ERCCl)的表达状况及其与患者临床病理特征、奥沙利铂方案化疗疗效及预后之间的关系。方法:采用免疫组化方法检测晚期结肠癌癌组织中ERCCl蛋白表达状况。结果:晚期结肠癌癌组织中ERCCl表达阳性表达率为45.1%。ERCCl蛋白的表达状况与患者的性别、年龄、肿瘤部位、分化程度及病理类型均无关(P>0.05)。ERCCl蛋白表达阴性患者奥沙利铂方案化疗有效率为56.0%高于表达阳性患者的34.1%(P=0.037),并且接受化疗后表达阴性患者中位生存期为19个月高于表达阳性患者的14个月(P=0.016)。结论:ERCCl蛋白表达阴性的晚期结肠癌患者接受奥沙利铂方案化疗有效率较阴性患者高并有生存受益,ERCCl的表达状态可作为晚期结肠癌化疗方案的选择及预后判断的指标。
OBJECTIVE: To investigate the expression of excision repair cross-complementing gene 1 (ERCCl) in advanced colon cancer and its relationship with clinicopathological features, efficacy and prognosis of oxaliplatin-based chemotherapy Relationship. Methods: The expression of ERCCl protein in advanced colorectal cancer tissues was detected by immunohistochemistry. Results: The positive rate of ERCCl expression in advanced colon cancer was 45.1%. The expression of ERCCl protein was not associated with the gender, age, tumor location, differentiation and pathological type (P> 0.05). The effective rate of oxaliplatin regimen in negative patients with ERCCl protein expression was 56.0%, higher than that in positive patients (34.1%) (P = 0.037), and the median survival time after negative chemotherapy was 19 months Of 14 months (P = 0.016). CONCLUSIONS: Patients with advanced colon cancer with negative ERCCl expression have a higher survival rate and survival benefit than those with negative control chemotherapy. The expression status of ERCCl can be used as an indicator of choice and prognosis of advanced colon cancer.